ESR1 and breast neoplasm: Roles for CXCR4 in resistance to endocrine treatments were also demonstrated when CXCL12 administration has increased the volumes of tumors generated by luminal-A breast tumor cells in mice treated by the estrogen receptor antagonist Fulvestrant (116).